Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021Cited by 618
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu‐Pei Chen, Nofisat Ismaila, Melvin L.K. Chua et al.|Journal of Clinical Oncology|2021Cited by 393
International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinomaAnne W.M. Lee, Joseph Wee, Chaosu Hu et al.|Radiotherapy and Oncology|2017Cited by 374
International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal CarcinomaAnne W.M. Lee, Joseph Wee, Wai Tong Ng et al.|International Journal of Radiation Oncology*Biology*Physics|2019Cited by 183
910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)Ezra E.W. Cohen, N. Lee, Robert L. Ferris et al.|Annals of Oncology|2020Cited by 42